GUMDROP : JHMI J1154 Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab or IMC18F1 or Without Investigational Therapy as Second line Therapy in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder

Created by Channing Paller, last modified on Apr 14, 2012

Description:

Hist-confirmed TCC of the bladder, urethra, ureter, or renal pelvis; locally advanced or metastatic and unresectable; progressed while on or within 12 months of platinum-based therapy; no more than 2 prior systemic checmo;  no more than 1 prior systemic trt for metastatic dx.

Link:

http://clinicaltrials.gov/ct2/show/NCT01282463

Site:

Johns Hopkins Hospital

Principal Investigator:

Jenny Kim, M.D.